GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chong Kun Dang Pharmaceutical 185750.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

62,300

-1.11%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.69trn

FY2016FY2025

Net income

₩77.51bn

FY2016FY2025

Free cash flow

−₩111.77bn

FY2016FY2025

Shareholders' equity

₩1.00trn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩1.69trn₩1.59trn₩1.67trn₩1.49trn₩1.34trn₩1.30trn₩1.08trn₩956.22bn₩884.36bn₩831.99bn
Gross profit₩526.38bn₩532.61bn₩662.20bn₩542.64bn₩495.82bn₩489.14bn₩404.28bn₩380.40bn₩359.66bn₩334.89bn
Research and development₩154.10bn₩143.91bn₩140.23bn₩176.32bn₩163.28bn₩146.66bn₩98.62bn₩77.03bn₩65.05bn₩67.18bn
Operating income₩80.57bn₩99.46bn₩246.60bn₩109.91bn₩94.76bn₩123.94bn₩74.58bn₩75.74bn₩77.76bn₩61.25bn
Net income₩77.51bn₩109.07bn₩212.52bn₩80.95bn₩42.72bn₩91.63bn₩53.88bn₩42.40bn₩53.81bn₩40.95bn
Diluted earnings per share7,519.3310,581.4820,617.317,853.534,144.438,889.575,227.224,111.535,220.003,972.30

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩1.80trn₩1.46trn₩1.40trn₩1.12trn₩1.05trn₩946.33bn₩801.35bn₩711.49bn₩677.21bn₩641.70bn
Total liabilities₩793.94bn₩562.39bn₩586.79bn₩503.59bn₩480.89bn₩394.74bn₩326.40bn₩280.60bn₩273.91bn₩287.45bn
Debt₩195.20bn₩115.95bn₩30.00bn₩110.51bn₩134.25bn₩54.99bn₩111.04bn₩104.47bn₩102.46bn₩124.57bn
Shareholders' equity₩1.00trn₩893.97bn₩815.69bn₩622.39bn₩566.01bn₩551.43bn₩473.52bn₩428.73bn₩401.71bn₩354.25bn
Shares outstanding10m10m10m10m10m10m10m10m10m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩67.36bn₩64.29bn₩318.16bn₩67.73bn₩12.90bn₩104.32bn₩77.29bn₩42.63bn₩81.67bn₩57.79bn
Capital spending−₩179.13bn−₩66.10bn−₩68.81bn−₩44.90bn−₩48.24bn−₩32.64bn−₩21.84bn−₩21.92bn−₩19.79bn−₩39.44bn
Free cash flow−₩111.77bn−₩1.81bn₩249.35bn₩22.84bn−₩35.34bn₩71.68bn₩55.45bn₩20.71bn₩61.88bn₩18.35bn
Dividends paid−₩13.82bn−₩13.33bn−₩11.61bn−₩11.24bn−₩10.81bn−₩9.28bn−₩8.84bn−₩8.46bn−₩8.46bn−₩5.64bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩478.47bn₩447.77bn₩426.78bn₩429.82bn₩434.85bn₩400.96bn₩415.36bn₩412.76bn
Gross profit₩140.46bn₩123.99bn₩130.50bn₩136.12bn₩136.36bn₩123.40bn₩130.56bn₩128.83bn
Operating income₩18.61bn₩14.09bn₩23.48bn₩20.99bn₩23.64bn₩12.45bn₩6.76bn₩26.02bn
Net income₩19.99bn₩12.82bn₩26.55bn₩20.10bn₩19.07bn₩11.78bn₩8.29bn₩21.85bn
Diluted earnings per share1,939.731,243.862,576.101,950.411,849.741,143.09804.052,119.53
Cash from operations₩13.31bn₩12.32bn₩76.18bn₩21.45bn−₩24.02bn−₩6.25bn₩20.25bn₩12.15bn
Capital spending−₩31.36bn−₩74.33bn−₩42.22bn−₩104.14bn−₩24.46bn−₩8.31bn−₩19.00bn−₩14.51bn
Free cash flow−₩18.05bn−₩62.02bn₩33.96bn−₩82.69bn−₩48.48bn−₩14.57bn₩1.24bn−₩2.37bn
Total assets₩1.87trn₩1.83trn₩1.80trn₩1.52trn₩1.50trn₩1.49trn₩1.46trn₩1.46trn
Debt₩275.37bn₩195.38bn₩195.20bn₩44.27bn₩104.62bn₩115.41bn₩115.95bn₩115.93bn
Shareholders' equity₩1.02trn₩1.03trn₩1.00trn₩942.74bn₩912.50bn₩890.31bn₩893.97bn₩893.03bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.4%5.4%11.1%
Operating income-9.8%-8.3%6.6%
Net income-1.4%-3.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.3%35.2%35.8%37.4%
Operating margin5.5%8.3%8.3%8.1%
Net margin5.7%7.5%6.8%5.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings11.08.46.09.523.121.014.518.518.017.8
Price to sales0.50.60.80.50.71.50.70.81.10.9

Dividends and splits

Per share, in the currency the company pays

Paid for 13 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year500.002,147.619907.03863.838783.526671.594671.594609.155
  • 1.05-for-1 split · 27 Dec 2024
  • 1.05-for-1 split · 27 Dec 2023
  • 21-for-20 split · 28 Dec 2022
  • 21-for-20 split · 29 Dec 2021
  • 21-for-20 split · 29 Dec 2020
  • 21-for-20 split · 27 Dec 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.